Determinants of virological failure among HIV clients on second-line antiretroviral treatment at Felege-hiwot and University of Gondar comprehensive specialized hospitals in the Amhara Region, Northwest Ethiopia: A case-control study

Getahun Ayenew; Yeshambel Agumas; Tebkew Shibabaw; Gebremariam Getaneh; Michael Getie

doi:10.1371/journal.pone.0289450

Abstract

Background

Second-line HIV treatment failure has become increasing worldwide, mainly in sub-Sahara Africa including Ethiopia. Even though the problem becomes increasing, inadequate information was available about its magnitude and associated factors in the current study area.

Objective

To assess the factors of second-line Anti-Retroviral Treatment virological failure among second-line ART users.

Method and materials

Institutional-based unmatched case-control study design was conducted from September to December 2021 at Felege Hiowt and University of Gondar Comprehensive Specialized Hospitals; Amhara region, Northwest Ethiopia. A total of 216 patients (60 cases and 156 controls) were recruited by a simple random sampling technique with a 1:3 cases-to-controls ratio. Patients who had two viral load results >1000 copies/ml within a 3-month interval after taking ART drugs for at least 6 months were cases and those who had ≤1,000 copies/ mL were controls. The sample size was calculated by using Epi-Info version 7.2.4. Structured questionnaires were used to gather the required information. SPSS version 26 was used to summarize the findings. In bivariate logistic regression model, Variables with two-tailed P-value ≤ 0.25 at 95% confidence interval were transferred into multivariate binary logistic regression model and P value at ≤ 0.05 was set as statistically significant.

Results

Out of 216 patients recruited, 212 have participated with a response rate of 98.2%. From these participants, 117(55.2%) were males and 187(88.2%) were urban dwellers. Among the total respondents, 208(98.1%) had age > 24 years, 200(94.3) were at HIV clinical stage I, 72(34%) had poor ART adherence and 112(52.8) did not disclose their HIV status. Likewise, most of the patients 147(69.37) didn’t use condoms. The associated factors were not disclosing HIV status (AOR = 3.4, 95% CI: 1.52–7.79), medium adherence (AOR = 3.7, 95% CI = 1.3–10.7), poor adherence level (AOR = 5.27, 95% CI: 2.2–12.5), not using condoms (AOR = 4.47, 95% CI: 1.63–12.2) and Viral load (>150 copies/ml) when switched to second-line ART (AOR = 3.56, 95% CI: 1.5–8).

Conclusion and recommendations

Non-disclosure, poor or medium adherence, not using condoms and high Viral load (>150 copes/ml) when switched to second-line ART were the main factors for second-line Anti-Retroviral Treatment virological failure. Disclosure about HIV status, using condoms and improving treatment adherence level are crucial to reduce second-line virological failure.

Citation: Ayenew G, Agumas Y, Shibabaw T, Getaneh G, Getie M (2024) Determinants of virological failure among HIV clients on second-line antiretroviral treatment at Felege-hiwot and University of Gondar comprehensive specialized hospitals in the Amhara Region, Northwest Ethiopia: A case-control study. PLoS ONE 19(7): e0289450. https://doi.org/10.1371/journal.pone.0289450

Editor: Yoon-Seok Chung, Korea Disease Control and Prevention Agency, REPUBLIC OF KOREA

Received: July 17, 2023; Accepted: February 20, 2024; Published: July 9, 2024

Copyright: © 2024 Ayenew et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Human immunodeficiency virus (HIV) has continued to be a major global public health issue, having claimed almost 40.4 million lives so far. About 85.6 million people have become infected with HIV since the start of the epidemic. Even though HIV infection prevention, diagnosis, treatment and care has increased, the disease remains a major public health threat worldwide due to the emergence of drug-resistant HIV [1, 2]. All current antiretroviral drugs (ARVD), including newer classes, are at risk of becoming partly or fully inactive [3, 4]. This results an increase in mortality, morbidity, HIV incidence and health care costs [5].

Viral load failure is used as a golden approach to confirm antiretroviral therapy (ART) failure. For HIV patients who started ART, Viral load testing should be performed early after initiating ART within 6 months, at 12 months and then at least every 12 months to detect treatment failure [5]. If a person on ART who has taken second-line ART drugs for at least 6 months has two consecutive viral load (Vl) results greater than 1000 copies/ml within a 3-month interval with adherence support between measurements, the results will confirm failure of the current treatment regimen and the client needs to be switched to appropriate third line regimen [5, 6].

Globally, the prevalence of drug resistant HIV (DRHIV) to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs has significantly increased since 2001. In Sub-Saharan Africa (SSA), Second-line HIV treatment failure has become highly prevalent with alarming rates during the 12–18-month period of treatment starts [7, 8]. Among patients receiving protease inhibitor (PI) based 2nd-line HIV treatment, 25% experienced virological failure at some point during follow-up [9]. A systematic review and meta-analysis conducted in SSA in 2019 also reported that the prevalence of Second-line HIV treatment failure was 13.4%. Of which 65% were PI-based and 35% were Ritonavir boosted PI-based second-line ART regimens [7]. The problem is observed more rapidly in Eastern Africa with an estimated annual incremental increase of 29%, Southern Africa (23%), Western and Central Africa (17%), Latin America (15%), and Asia (11%). In eastern Africa, the Prevalence of pretreatment NNRTI resistance increased from 0% in 1996 to 13% in 2016 [7, 10, 11]. In resource-limited countries, HIV drug resistance is still a serious threat to their health [3]. The prevalence of second-line virological ART failure rates among adults in 2012 in these country were 21.8–33%, 14–38%, 15–38.5% and 10–38.0% at 6, 12, 24, and 36 months of initiation on second-line ART respectively [12]. There were 1668 patients with virological failure in south Africa in 2012 [13], 109 patients with confirmed second-line virological failure in Malawi in 2010 [14]. Second-line ART Virological failure was 18% in Rwanda by the end of 2016 [15]. Some Studies in Tanzania and southeast Uganda also indicated that there were high incidence of virological failure on second-line ART [16, 17].

The magnitude of virological treatment failure is increasing from time to time in Ethiopia [18]. It becomes a major challenge for HIV AIDS prevention and control mechanisms. The adjusted magnitude of second-line virological failure (VF) among the population taking ART in Ethiopia was found to be 11% [19]. According to a study done among children and adolescents on second line ART in a pediatric cohort of an Ethiopian tertiary hospital, the proportion of treatment failure (TF) was 14 out of 76 patients [20]. A high incidence rate of second-line treatment failure (9.86 per 100 person-years or 254/1011) was also noticed in Amhara Region in 2016 [21].

Among the determinants of second-line ART failure, poor adherence to ART, high viral load, not disclosure about HIV status, opportunistic infection, low CD4 counts < 350 cell/mm³, low BMI (< 16 kg/m²), young age (15–29 years old) patients, WHO HIV clinical stage, TB co-morbidity, smoking and drug abuse were found to be the main factors [7, 15, 21–26].

Even if the problem is rising, there is still a dearth of information in developing countries on the factors for second-line ART failure [14]. Data available on this regard is limited in the current study area. Hence, identifying the risk factors of second-line treatment failure stays crucial to reduce treatment failure on this regimen and the need for third-line drugs [27]. Most of the previous studies conducted in Ethiopia were focused on first-line ART drug resistance. Despite few investigations were done in this field, clinical and immunological characteristics of the patient were used to rule out ART failure, which is not recommended whenever viral load monitoring is possible. Therefore, identifying the factors of second-line ART virological failure among patients on ART was the main objective of this study.

Findings of this research will give information about the risk factors of second-line ART virological failure in the current study area. It will serve as a base line data for treatment centers to address factors related to second line treatment failure. The result might be useful for stakeholders to set programs and action plans on the need to third line regimens. It will be used as a source of information for researchers. It will also give important recommendations for patients on their treatment.

Methods and materials

Study settings

The study was conducted at Felegehiwot and University of Gondar comprehensive specialized hospitals in the Amhara region, Northwest Ethiopia. Felegehiwot Comprehensive Specialized Hospital (FHCSH) is found in Bahir Dar city, the capital city of Amhara Regional state. It is located 567km away from Addis Abeba. According to the Amhara National Regional State Plan Commission Bureau 2021 data, Bahir Dar city administration had an estimated total population of 412,189 (206,412 male and 205,777 female) dwellers. Of which 85% live in the urban and 15% in the peri-urban and rural areas of the city [28, 29]. Based on Amhara Regional health bureau 2021 report, 14 Health posts, 10 Health centers 2 general hospitals and 2 referral hospitals are governmental health institutions found in the city. There are also 10 basic clinics, 28 Medium clinics, 10 higher clinics and 5 general hospitals among private health institutions. Only one governmental specialized referral hospital (Felege Hiwot) has provided third line ART treatment service in Bahir Dar [30]. There were 740 and 31 ART patients who were on second line and third-line regimens respectively at FHCSH by the end of August 2021.

The city of Gondar is situated in North-western parts of Ethiopia, Amhara Regional State. It far 725 km from Addis Ababa, 175 km from Bahir Dar and 120km from the Simien Mountains. The Regional Plan Commission Bureau also reported that, the metro area population of Gondar city in 2021 was 454,445 (218,378 male and 236,068 female) [29, 31]. University of Gondar Comprehensive Specialized Hospital (UGCSH) is used as the referral center for more than 7 million catchment population [32]. Based on reports obtained from this hospital, there were 5513 patients on ART until September 1^st, 2021. Out of these 520 were second-line ART users and 29 were on third-line regimens.

Study design and period

Institutional-based unmatched case-control study design was conducted from September first, 2021, to December last 2021.

Source population

All HIV patients at FHCSH and UGCSH who were on second-line ART regimens.

Study population

All HIV patients on ART at FHCSH and UGCSH who took second line ART for more than six months and had two subsequent viral load measurements within a 3-month interval during the study period.

Inclusion and exclusion criteria

All HIV patients who were on second-line ART at FHCSH and UGCSH ART clinics during the study period were included. Whereas those patients who had not taken a second-line ART regimen for more than six months and who didn’t have two subsequent viral load measurements within a 3-month interval during the study period were excluded from the study.

Sample size determination and sampling techniques

Sample size was calculated using EPIINFO version 7.2.4 (a two-population proportion formula). The following assumption were considered during sample size calculation. Confidence level 95%, Z α/2 = 1.96 (for 0.05 significance level); for 80% power, Z_β = 0.84, ratio of controls to cases = 3:1, p1 = 31% (% of cases among exposed), p2 = 11.2% (% of cases among non-exposed). Key predictors of second-line ART virologic failure from a previous study carried out in Wollo, Northeast Ethiopia, were used a base line data [26]. Hence, the minimum sample size including 10% non-respondent rate for this study was 216 participants, 60 cases and 156 controls. The list of clients with their viral load results were extracted from the patients registration book in each ART clinic of study facilities. Then 31 patients at FHCSH and 29 patients at UGCSH who had a viral load result >1,000 copies/mL in two subsequent viral load measurements within a 3-month interval were selected. Likewise, 94 patients from FHCSH and 62 patients from UGCSH who didn’t develop a virological failure were recruited based on proportional allocation by using a computer generated simple random sampling method.

Study variables

Independent variables were Socio demographic, behavioral, clinical, and immunological characteristics of the patient. Of these; sex, age, residence, marital status, educational status, alcohol intake, drug abuse, smoking, disclosure status, condom use, adherence, body mass index (BMI), opportunistic infections (OI), TB coinfection, nutritional status, WHO HIV clinical staging at switch to second line, CD4 count (CD4 count at 2^nd line ART initiation), viral load, type of first and second line treatment (being on a protease inhibitor plus 2 nucleoside analogues(NRTIs) or not), duration in second line ART and duration in first line ART. Whereas the dependent variable (outcome of interest) was second line ART virological failure.

Data collection tools and techniques

The data were collected by using structured questionnaires and checklist prepared by the principal investigator. The tools were adapted from different literatures, WHO guidelines, institutional checklists, and some of it were developed by the investigators. This tool includes socio demographic, behavioral, clinical, and immunological related data. Personal interview and patient registration book/ card/ review was performed using data collection tools to gather the required information.

Data quality managements

To maintain the data quality, different techniques were employed to address major source of errors. The questionnaires were translated to local language (Amharic). Health professionals who were participated in the data collection were got on sight training before the data collection. Each day the collected data were cross checked for its completeness, accuracy, clarity, consistency and missed values and missed variables carefully. Necessary modifications were made based on the gaps identified. All collected data were entered into EPI-data version 3.1 after being coded. Then it was transferred to Statistical Package for Social Science (SPSS) version 26 for analysis.

Data processing and analysis

The collected data were entered and analyzed by using SPSS version 26 for windows. Descriptive statistics was used to present and summarize the findings. Bivariate and multivariate binary logistic regression model was employed to identify determinants of second line ART virological failure. Odds ratios with its 95% confidence intervals and two-tailed P-value was calculated. Variables with P-value ≤ 0.25 in the bivariate analysis were included in the multivariate logistic regression model and variables that had a P value ≤ 0.05 in the multivariate analysis were considered statistically significant.

Ethical statement

This investigation was approved by Bahir Dar University, College of Medicine and Health Sciences Institutional Review Board (P. No-317/2021). Official letter of co-operations was provided to FHCSH and UGCSH prior to data collection. Assent from children and verbal informed consent from adults were obtained after explaining the purpose and objective of the study. Confidentiality of the data had been maintained.

Definition of terms

Stable on ART- HIV Patients on ART for at least 1 year, no current illnesses or pregnancy, good understanding of lifelong adherence and evidence of treatment success (two consecutive viral load measurements below 1000 copies/mL) and absence of adverse drug reactions requiring regular monitoring [5].

Adherence- Refers to the whole process from starting HIV treatment, keeping all medical appointments and taking HIV medicines every day and exactly as prescribed. Or it is the degree to which the person’s behavior, taking medication, following a diet and/or changing lifestyle corresponds with the agreed recommendations from a health care provider [5].

Good Adherence; drug adherence of ≥95% or if <2 doses of 30 doses or <3 doss of 60 doses is missed as documented by ART healthcare provider [5].

Fair/medium/ adherence. Drug adherence of 85–94% or 3–5 missed drug doses out of 30 doses or 4–9 missed drug doses out of 60 doses [5].

Poor adherence; If drug adherence is <85% or ≥6 doses of missed ART drug doses out of 30 doses or >9 doses of missed ART drug doses out of 60 as documented by the ART healthcare provider [5].

Suboptimal adherence; a report of ≥1 reason for missing ART ≥5 times within the past month [33]

Opportunistic Infections (OI); Infections that develop as a result of HIV-inflicted damage to the immune system (TB, PCP, gastrointestinal OI, herpes simplex, herpes zoster, fungal infection) and other national ART guidelines define opportunistic infection [6].

Virological failure; refers to a persistently detectable viral load exceeding 1000 copies/mL (two consecutive viral load measurements within a 3-month interval with adherence support between measurements) after at least 6 months of using ART [5]

Non-Disclosure: patients who did not disclose about their HIV status for anyone except their health care providers who give the service.[5]

Results

Socio-demographic and behavioral characteristics

Out of the total of 216 patients on second-line ART (60 cases and 156 controls) recruited, 212 (59 cases and 153 controls) were participated in this study. This accounts for a response rate of 98.2%. The mean age of the participants were 40.7 years old. Among the participants, 117 (55.2%) were males and 187 (88.2%) respondents were urban residents. The majority of respondents 208 (98.1%) were above 24 years old, and only 4 (1.9%) were 24 years old or below. There were 102 (48.1%) married participants and 73 (34.4%) who had an elementary level of education (Table 1).

Download:

Table 1. Socio demographic characteristics of patients on second-line ART at FHCSH and UGCSH; Amhara Region, Northwest Ethiopia from September to December 2021.

https://doi.org/10.1371/journal.pone.0289450.t001

From the study participants, 33 (55.9%) of the cases and 3(2%) of the controls had poor adherence to ART treatments. Similarly, 46 (78%) of the cases and 66 (43.1%) of the controls did not disclose their HIV status while taking ART. Likewise, 9 (15.3%) of the cases and 26 (17%) of the controls had a history of alcohol use. Most of the cases 53 (89.8%) and the controls 94 (61.4%) did not used condoms (Table 2).

Download:

Table 2. Behavioral characteristics of patients on second-line ART at FHCSH and UGCSH; Amhara Region, Northwest Ethiopia from September to December 2021.

https://doi.org/10.1371/journal.pone.0289450.t002

Clinical and immunological characteristics

Among the participants recruited, 86(40.6%) had a CD4 count <200 (cells/mm3). Eight (13.6%) of the cases and 7(4.6%) of the controls were severely malnourished. Viral load when switched to second-line ART is ≥1000(copes/ml) for 71(33.5%) patients. Most of the participants were at WHO HIV clinical stage I (Table 3).

Download:

Table 3. Clinical and immunological characteristics of patients on second-line ART at FHCSH and UGCSH; Amhara Region, Northwest Ethiopia from September to December 2021.

https://doi.org/10.1371/journal.pone.0289450.t003

Factors associated to second line ART virological failure

In bi-variable logistic regression analysis the following variables; Not using condoms, Non-disclosure about HIV status, poor Level of Adherence, sever acute malnutrition nutritional status and Viral load >150 copes/ml when switched to second line ART were selected for further multivariable binary logistic regression analysis (P-value<0.25) (Table 4).

Download:

Table 4. Factors associated to second line ART virological failure among second-line HIV patients at FHCSH and UGCSH; Amhara Region, Northwest Ethiopia from September first, 2021, to December last 2021.

https://doi.org/10.1371/journal.pone.0289450.t004

In the multivariable binary logistic regression analysis, Not using condoms, non-disclosure about HIV status, poor or medium level of adherence and viral load ≥150 copes/ml when switched to second line ART had a significant impact on second line ART outcomes. Peoples who did not disclosed their HIV status were 3 times (AOR = 3.4, 95% CI: 1.52–7.79) more likely to develop second-line ART virological failure as compared to those patients who did. Among the respondents those patients who had poor and medium level of adherence were 5 times (AOR = 5.27, 95% CI = 2.2–12.5) and 3.7 times more likely to develop second line ART virological failure respectively as compared to those who had a good adherence (Table 4).

Moreover, the likelihood of developing second line virological failure among patients with Viral load ≥1000 copes/ml when switched to second-line ART medication were 3.5 times (AOR = 3.56, 95% CI: 1.5–8) more as compared to those patients with Viral load result <150 copes/ml. Similarly, those patients with VL>150–999 copies/ml had 5 times more to develop virological failure as compared to those with VL<150 copies /ml. (Table 4).

Discussion

This study was aimed to assess factors for virological failure among second-line ART users. Poor or medium level of adherence to ART, non-disclosure about HIV status, not using condoms and having Viral load >150 copes/ml when switched to second line ART were the factors that increased the odds of second line ART virological failure.

Patients who had poor and medium ART adherence were 5 times and 3.7 times more likely to develop second line ART virological failure as compared to patients who had good treatment adherence. Similar findings were reported in Wollo, Amhara Regional State Northeast Ethiopia and Northern Ethiopia where the odds of developing second line ART virologic failure was strongly associated with poor ART adherence [22, 34]. This finding is supported by a study conducted in Johannesburg, South Africa [27], Southwestern Nigeria [35], sub-Saharan Africa and Asia which showed that poor or medium adherence was a strong predictor of second-line ART failure [7, 23]. Another investigation done in Cambodia (Southeast Asian) also confirmed that, patients on second line ART with good adherence were significantly associated with viral suppression [24].

ART adherence is generally regarded as an important factor in achieving optimal treatment outcomes. High levels of treatment adherence to ART results to effective viral suppression outcomes. Poor adherence to ART is the most frequent cause of treatment failure and the subsequent development of drug resistant strains of HIV. If the patients do not always take their medications as prescribed, the virus will replicate and develop new resistance mutations over time. Missing doses can lead to low drug levels in the body, which allows the virus to resume replication and accumulate resistance mutations as it multiplies. This results less effective viral suppression and a rise in plasma viral load. Inadequate suppression of viral replication has a continued destruction of CD4 cells, progressive decline in immune function and disease progression, Limited future treatment options and higher costs to the individual and ARV program. Even though these risks the immediate health of the patient, it is also an important reason for the emergence of viral resistance to one or more antiretroviral medications [36, 37].

The study found that, not using condom was one of the factors for second line ART virological failure. Patients who didn’t use condom were 4 times more likely to develop ART failure than those who used.

Inconsistent use of a condom by people living with HIV/AIDS on ART has led to further risk of new HIV infection and the development of reinfection with new drug-resistant viral strains. Using condom prevents from acquiring and transmitting drug resistant HIV infection. Patients on ART may also acquire transmitted drug resistant HIV virus if they do not use condoms. This type of HIV infection results treatment failure among ARV drug–naive people with no history of ARV drug exposure [3, 38]. Not using Condom also exposed for many sexually transmitted infections (STI) that leads to further worsening the HIV infection by dipping the immune system. So that ART may not be effective and new drug resistant viral strains may occur [39].

The study also identified that patients who had a high viral load (≥1000 copies/ml) when switched to second line ART were 3.5 times more likely to develop second-line ART virological failure than those patients who had suppressed viral load (<150 copies/ml). This outcome is supported by studies conducted in Sub-Saharan Africa and Johannesburg, South Africa in which they presented that high viral load was a significant predictor for second line ART virological failure [7, 27].

Different literature stated that a high viral load can lead to a low CD4 cell count which in turn increases the risk of developing an illness or infection. Circulating high viral particles in blood results high destruction of the immune system (CD4 cell) which in turn aggravates disease progression. Finally, it will lead to the emergence of resistant viral strains. This indicates the treatment is not working well. The higher the viral load, the more risk developing treatment failure [40].

In addition, our investigation identified that the odds of developing second line virological ART failure was increased by 3 folds for patients who did not disclose their HIV status as compared to their counter parts.

Previous studies conducted in Wollo, Amhara Regional State, Northeast Ethiopia and Johannesburg, South Africa also reported that not disclosing HIV status was the main risk factors for virological ART failure [27, 34]. But a study conducted in a post-conflict area in Northern Uganda have reported its impact on treatment outcomes. It showed that HIV-infected people have got confronted discrimination, stigmatization, and violence following their disclosure. This may be patients in conflict-afflicted areas may in specific confront exceptional challenges, and their need for social support may be aggravated [41].

Most studies had agreed that disclosure play a significant role in good ART outcomes [42]. People who achieved full disclosure about their HIV status had lower viral load (improved viral suppression), increased ART adherence and allowed for better self-care and treatment. Patients who disclosed about their HIV status have good adherence to ART compared with those who did not. Studies have found that patients who disclosed their sero-status had better social support; stronger family and relationship cohesion; reductions in anxiety and depression; improvements in physical health, emotional support, and financial support; and were better able to take their ART freely. Talking about having HIV may lead to increased trust and feelings of intimacy in a relationship or close friendship and a feeling of empowerment. This helps to have a higher chance of being supported by loved ones and partners. For example, disclosing for health professionals such as doctor, dentist, pharmacist, or psychologist will mean that they are better able to provide appropriate care that meets the patients’ needs as a person living with HIV. These helps to improve their ART adherence and having lower risk of developing ART failure. Patients who did not disclosed their HIV status were at high risk of developing Virological failure [43–45].

Although disclosure comes with a sense of alleviation and potential support, it also bears challenges like stigma, discrimination, and violence. Such perceptions make disclosure is not easier. To address this barrier, different methods are recommended. HIV care providers and counsellors should be trained by emphasising the positive outcomes of disclosure and provide frequent counselling service. They also prepare their clients to handle the potential negative outcomes and raise their awareness about the benefits of HIV disclosure. Selecting targets to be disclosed for the first time based on relationship quality and target opinions helps to reduce psychological stress and to adapt disclosure. Timing of disclosure should be carefully planned to minimize rejection and maximize fairness to others. Patients should be ready enough to overcome side effect of disclosure before they do to reduce the possible challenges [42, 46].

Conclusions

The study identified that poor or medium adherence to ART medication, non-disclosure about HIV status, not using condom and high viral load >150 copies/ml were significantly associated with second-line ART virological failure.

Recommendations

Patients on ART should not miss their medication for any reasons and use their full efforts to have good ART adherence. Disclosing their HIV status and using condom will have an incredible benefit in terms of social supports and to get early ART treatment. Early identification of patients who had poor adherence, non- disclosed and high viral load will be an important task to reduce ART failure. Such patients will need closer clinical follow-up to minimize the risk of treatment failure. Further investigation is needed to explore factors associated with poor adherence and not disclosing HIV status.

Supporting information

S1 File. Annex I. Information sheet.

https://doi.org/10.1371/journal.pone.0289450.s001

(DOCX)

S2 File. Annex II Consent form.

https://doi.org/10.1371/journal.pone.0289450.s002

(DOCX)

S1 Table. Socio demographic characteristics of the patients.

https://doi.org/10.1371/journal.pone.0289450.s003

(DOCX)

S2 Table. Behavioral characteristics of the patients.

https://doi.org/10.1371/journal.pone.0289450.s004

(DOCX)

S3 Table. Clinical and immunological features of the patients.

https://doi.org/10.1371/journal.pone.0289450.s005

(DOCX)

S4 Table. Factors for second line ART Virological failure.

https://doi.org/10.1371/journal.pone.0289450.s006

(DOCX)

Acknowledgments

First, I would like to acknowledge Bahir Dar University College of medicine and health sciences, school of public health, department of health system management and health economics for give me a chance to conduct research on this topic and for its approval.

I also acknowledge the Felege Hiwot Comprehensive Specialized Hospital and University of Gondar Comprehensive Specialized Hospital for their co-operative and supportive willingness to our work.

I would like to thank Mr Melkamu Teshager and Mis Aynalem Mihiret who were participated in our work by data collection.

References

1. World Health Organozation. HIV and AIDS. WHO. 2023 [cited 2024 Feb 2]. In WHO newsroom. [Internet], [about 2 screens], Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids?gclid
2. UNAIDS. Global HIV & AIDS statistics—Fact sheet. UNAIDS.2021 [cited 2024 Feb 2]. [Internet]. Available from: https://www.unaids.org/en/resources/fact-sheet
3. Pennings PS. HIV drug resistance: Problems and perspectives. Infect Dis Rep. 2013;5(SUPPL.1):21–5. pmid:24470969
- View Article
- PubMed/NCBI
- Google Scholar
4. Melku M, Gesesew HA, Ward PR. Magnitude and predictors of HIV-Drug resistance in Africa: A protocol for systematic review and meta-analysis. PLoS One. 2022 Apr 1;17(4): pmid:35442975
- View Article
- PubMed/NCBI
- Google Scholar
5. World Health Organization. Clinical guidelines: antiretroviral therapy. In: WHO, editor. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. second ed. swezerland,Jeneva: World Health Organization; 2016. p. 71–150.
6. Ethiopia Federal Ministry ofHealth. National consolidated guidelines for comprehensive HIV prevention, care and treatment WHO Regional Office for Africa. Second. ed. EMOH, editor. Ethiopia, Addis Abeba: WHO; 2018. 42–151 p.
7. Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in subSaharan Africa: A systematic review and metaanalysis. PLoS One. 2019 Jun 1;14(7): pmid:31356613
- View Article
- PubMed/NCBI
- Google Scholar
8. Jordan MR, Hamunime N, Bikinesi L, Sawadogo S, Agolory S, Shiningavamwe AN, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Med (United States). 2020 Sep 11;99(37):E21661. pmid:32925712
- View Article
- PubMed/NCBI
- Google Scholar
9. Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 Sep 15;214(6):873–83. pmid:27402780
- View Article
- PubMed/NCBI
- Google Scholar
10. Vaz P, Buck WC, Bhatt N, Bila D, Auld A, Houston J, et al. Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure. J Pediatric Infect Dis Soc. 2020;9(1):6–13. pmid:30364958
- View Article
- PubMed/NCBI
- Google Scholar
11. WHO Team. Global action plan on HIV drug resistance 2017–2021. Second. WHO, editor. WHO. swezerland,Jeneva: World Health Organization; 2023. 1–40 p.
12. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929–38. pmid:22313953
- View Article
- PubMed/NCBI
- Google Scholar
13. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):370–80. pmid:22820803
- View Article
- PubMed/NCBI
- Google Scholar
14. Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010 Mar 1;11(8):510–8. pmid:20345885
- View Article
- PubMed/NCBI
- Google Scholar
15. Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019 Apr 5;19(1):312. pmid:30953449
- View Article
- PubMed/NCBI
- Google Scholar
16. Agegnehu CD, Merid MW, Yenit MK. Incidence and predictors of virological failure among adult HIV patients on first-line antiretroviral therapy in Amhara regional referral hospitals; Ethiopia: a retrospective follow-up study. BMC Infect Dis. 2020 Jul 1;20(1):460. pmid:32611405
- View Article
- PubMed/NCBI
- Google Scholar
17. Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, et al. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. AIDS Res Ther. 2021 Dec 1;18(1):1–10.
- View Article
- Google Scholar
18. Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: A case-control study. BMC Infect Dis. 2019 Apr 3;19(1):305. pmid:30943903
- View Article
- PubMed/NCBI
- Google Scholar
19. Egziabhier AG, Zealiyas K, Tilahun R, Girma M, G/Michael G, Deressa T, et al. HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia. J AIDS HIV Treat. 2019 Nov 22;Volume 1(Issue 2):46–57.
- View Article
- Google Scholar
20. Alemayehu T, Abebe W. Second line anti-retroviral therapy failure in a pediatric cohort of an Ethiopian tertiary hospital: a retrospective observational study. Sci Rep. 2020 Dec 1;10(1):8699. pmid:32457309
- View Article
- PubMed/NCBI
- Google Scholar
21. Alene M, Awoke T, Yenit MK, Tsegaye AT. Incidence and predictors of second-line antiretroviral treatment failure among adults living with HIV in Amhara region: A multi-centered retrospective follow-up study. BMC Infect Dis. 2019 Jul 9;19(1):599. pmid:31288748
- View Article
- PubMed/NCBI
- Google Scholar
22. Zenebe Haftu A, Desta AA, Bezabih NM, Bayray Kahsay A, Kidane KM, Zewdie Y, et al. Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study. Edward ST, editor. PLoS One. 2020 Sep 28;15(9):e0239191. pmid:32986756
- View Article
- PubMed/NCBI
- Google Scholar
23. Teeraananchai S, Kerr SJ, Gandhi M, Do VC, Van Nguyen L, Tran DNH, et al. Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):253–6. pmid:31125411
- View Article
- PubMed/NCBI
- Google Scholar
24. Ségéral O, Nerrienet E, Neth S, Spire B, Khol V, Ferradini L, et al. Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Front Public Heal. 2018 Mar 19;6:63. pmid:29662875
- View Article
- PubMed/NCBI
- Google Scholar
25. Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: Adolescents at high risk of failure. J Int AIDS Soc. 2017;20(1): pmid:28953325
- View Article
- PubMed/NCBI
- Google Scholar
26. Seid A, Cherie N, Ahmed K. Determinants of Virologic Failure Among Adults on Second Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia. HIV/AIDS—Res Palliat Care. 2020 Nov 10;Volume 12:697–706. pmid:33204171
- View Article
- PubMed/NCBI
- Google Scholar
27. Onoya D, Nattey C, Budgell E, Van Den Berg L, Maskew M, Evans D, et al. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa. AIDS Patient Care STDS. 2017 May 1;31(5):205–12. pmid:28445088
- View Article
- PubMed/NCBI
- Google Scholar
28. Adigeh DT, Abebe BG. The Practice of Peri-Urban Land Acquisition by Expropriation for Housing Purposes and the Implications: The Case of Bahir Dar, Ethiopia. Urban Sci. 2023 Jun 1;7(2):
- View Article
- Google Scholar
29. Mekonen D, Arega Bazezew |, Mesfin Anteneh |, Kassie T. Analysis of food security using various indicators for policy implications: Empirical evidence from the two large cities of Bahir Dar and Gondar, the Amhara region, Ethiopia. Geo Geogr Environ. 2023 Jan 1;10(1):e00122.
- View Article
- Google Scholar
30. Asemahagn MA. The functionality status and challenges of electronic health management information system: The case of public health centres in Amhara Region, Ethiopia. Cogent Med. 2018 Jan 1;5(1):1437672.
- View Article
- Google Scholar
31. Tegegne AD, Negewo MAP, Desta MK, Nedessa KG, Belaye HM. CITY PROFILE GONDAR. In: Social Inclusion and Energy Managment for Informal Urban Settlements. GOdar Ethiopia: Semantic Scholar; 2020. p. 1–28.
32. Taddese AA, Gashaye KT, Dagne H, Andualem Z. Maternal and partner’s level of satisfaction on the delivery room service in University of Gondar Referral Hospital, northwest, Ethiopia: a comparative cross-sectional study. BMC Heal Serv Res 2020 201. 2020 Mar 19;20(1):1–8.
- View Article
- Google Scholar
33. De los Rios P, Okoli C, Punekar Y, Allan B, Muchenje M, Castellanos E, et al. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Prev Med (Baltim). 2020 Oct 1;139(106182): pmid:32593732
- View Article
- PubMed/NCBI
- Google Scholar
34. Tsegaye AT, Wubshet M, Awoke T, Addis Alene K. Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: A multicentre retrospective follow-up study. BMJ Open. 2016 Dec 1;6(12):e012537. pmid:27932339
- View Article
- PubMed/NCBI
- Google Scholar
35. Usman SO, Ajayi OM, Ebiekura O, Egbonrelu N, Ebhojie G, Ariyo AO. Evidence of virological failure in patients on second-line anti-retroviral therapy in Southwestern Nigeria: An indication for HIV drug resistance testing. African J Clin Exp Microbiol. 2021 Jul 2;22(3):415–9.
- View Article
- Google Scholar
36. Silva Junior G, Parente Filho SL, Soares D, Alencar R, Peixoto T, Nogueira I, et al. Factors associated with poor adherence to ant-retroviral therapy among HIV/AIDS patients attending care and treatment clinic at Mnazi Mmoja Hospital, Zanzibar. Int J Infect Dis. 2018 Aug 1;73:250–1.
- View Article
- Google Scholar
37. Kenneth L. Schaecher FACP, CPC MD. The Importance of Treatment Adherence in HIV. Suppl Featur Publ. 2013;19(12 Suppl):1–9.
- View Article
- Google Scholar
38. Yeshaneh A, Lencha A, Aweke AM, Dessalew Y, Wale T, Mekuriya E, et al. Consistent condom utilization and associated factors among HIV positive clients attending ART clinic at Pawi general hospital, North West Ethiopia. PLoS One. 2021 Dec 1;16(12):e0261581. pmid:34932611
- View Article
- PubMed/NCBI
- Google Scholar
39. Ali MS, Tesfaye Tegegne E, Kassa Tesemma M, Tesfaye Tegegne K. Consistent Condom Use and Associated Factors among HIV-Positive Clients on Antiretroviral Therapy in North West Ethiopian Health Center, 2016 GC. AIDS Res Treat. 2019;2019: pmid:31007955
- View Article
- PubMed/NCBI
- Google Scholar
40. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA. 2001 Nov 28;286(20):2560–7. pmid:11722270
- View Article
- PubMed/NCBI
- Google Scholar
41. Mugisha K, Ocero A, Semafumu E, Ciccio L, Muwanika RF, Otim J, et al. Retention of HIV positive persons in antiretroviral therapy programs in post-conflict northern uganda-baseline survey of 17 health units. Rep by North Uganda Malaria, AIDS, Tuberc Program. 2009;7(2):8–42.
- View Article
- Google Scholar
42. Dessalegn NG, Hailemichael RG, Shewa-amare A, Sawleshwarkar S, Lodebo B, Amberbir A, et al. HIV Disclosure: HIV-positive status disclosure to sexual partners among individuals receiving HIV care in Addis Ababa, Ethiopia. PLoS One. 2019 Feb 1;14(2):e0211967. pmid:30768642
- View Article
- PubMed/NCBI
- Google Scholar
43. Izudi J, Okoboi S, Lwevola P, Kadengye D, Bajunirwe F. Effect of disclosure of HIV status on patient representation and adherence to clinic visits in eastern Uganda: A propensity-score matched analysis. PLoS One. 2021 Oct 19;16(10):e0258745. pmid:34665842
- View Article
- PubMed/NCBI
- Google Scholar
44. Dessie G, Wagnew F, Mulugeta H, Amare D, Jara D, Leshargie CT, et al. The effect of disclosure on adherence to antiretroviral therapy among adults living with HIV in Ethiopia: A systematic review and meta-analysis. BMC Infect Dis. 2019 Jun 17;19(1):1–8.
- View Article
- Google Scholar
45. Beima-Sofie KM, Brandt L, Hamunime N, Shepard M, Uusiku J, John-Stewart GC, et al. Pediatric HIV Disclosure Intervention Improves Knowledge and Clinical Outcomes in HIV-Infected Children in Namibia. J Acquir Immune Defic Syndr. 2017 May 1;75(1):18–26. pmid:28114186
- View Article
- PubMed/NCBI
- Google Scholar
46. Melis Berhe T, Lemma L, Alemayehu A, Ajema D, Glagn M, Dessu S. HIV-Positive Status Disclosure and Associated Factors among HIV-Positive Adult Patients Attending Art Clinics at Public Health Facilities of Butajira Town, Southern Ethiopia. AIDS Res Treat. 2020;7(16): pmid:33204528
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. World Health Organozation. HIV and AIDS. WHO. 2023 [cited 2024 Feb 2]. In WHO newsroom. [Internet], [about 2 screens], Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids?gclid

[ref2] 2. UNAIDS. Global HIV & AIDS statistics—Fact sheet. UNAIDS.2021 [cited 2024 Feb 2]. [Internet]. Available from: https://www.unaids.org/en/resources/fact-sheet

[ref3] 3. Pennings PS. HIV drug resistance: Problems and perspectives. Infect Dis Rep. 2013;5(SUPPL.1):21–5. pmid:24470969
View Article
PubMed/NCBI
Google Scholar

[4] View Article

[5] PubMed/NCBI

[6] Google Scholar

[ref4] 4. Melku M, Gesesew HA, Ward PR. Magnitude and predictors of HIV-Drug resistance in Africa: A protocol for systematic review and meta-analysis. PLoS One. 2022 Apr 1;17(4): pmid:35442975
View Article
PubMed/NCBI
Google Scholar

[8] View Article

[9] PubMed/NCBI

[10] Google Scholar

[ref5] 5. World Health Organization. Clinical guidelines: antiretroviral therapy. In: WHO, editor. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. second ed. swezerland,Jeneva: World Health Organization; 2016. p. 71–150.

[ref6] 6. Ethiopia Federal Ministry ofHealth. National consolidated guidelines for comprehensive HIV prevention, care and treatment WHO Regional Office for Africa. Second. ed. EMOH, editor. Ethiopia, Addis Abeba: WHO; 2018. 42–151 p.

[ref7] 7. Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in subSaharan Africa: A systematic review and metaanalysis. PLoS One. 2019 Jun 1;14(7): pmid:31356613
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref8] 8. Jordan MR, Hamunime N, Bikinesi L, Sawadogo S, Agolory S, Shiningavamwe AN, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Med (United States). 2020 Sep 11;99(37):E21661. pmid:32925712
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref9] 9. Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. J Infect Dis. 2016 Sep 15;214(6):873–83. pmid:27402780
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref10] 10. Vaz P, Buck WC, Bhatt N, Bila D, Auld A, Houston J, et al. Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure. J Pediatric Infect Dis Soc. 2020;9(1):6–13. pmid:30364958
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref11] 11. WHO Team. Global action plan on HIV drug resistance 2017–2021. Second. WHO, editor. WHO. swezerland,Jeneva: World Health Organization; 2023. 1–40 p.

[ref12] 12. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929–38. pmid:22313953
View Article
PubMed/NCBI
Google Scholar

[31] View Article

[32] PubMed/NCBI

[33] Google Scholar

[ref13] 13. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):370–80. pmid:22820803
View Article
PubMed/NCBI
Google Scholar

[35] View Article

[36] PubMed/NCBI

[37] Google Scholar

[ref14] 14. Hosseinipour M, Kumwenda J, Weigel R, Brown L, Mzinganjira D, Mhango B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010 Mar 1;11(8):510–8. pmid:20345885
View Article
PubMed/NCBI
Google Scholar

[39] View Article

[40] PubMed/NCBI

[41] Google Scholar

[ref15] 15. Nsanzimana S, Semakula M, Ndahindwa V, Remera E, Sebuhoro D, Uwizihiwe JP, et al. Retention in care and virological failure among adult HIV+ patients on second-line ART in Rwanda: a national representative study. BMC Infect Dis. 2019 Apr 5;19(1):312. pmid:30953449
View Article
PubMed/NCBI
Google Scholar

[43] View Article

[44] PubMed/NCBI

[45] Google Scholar

[ref16] 16. Agegnehu CD, Merid MW, Yenit MK. Incidence and predictors of virological failure among adult HIV patients on first-line antiretroviral therapy in Amhara regional referral hospitals; Ethiopia: a retrospective follow-up study. BMC Infect Dis. 2020 Jul 1;20(1):460. pmid:32611405
View Article
PubMed/NCBI
Google Scholar

[47] View Article

[48] PubMed/NCBI

[49] Google Scholar

[ref17] 17. Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, et al. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. AIDS Res Ther. 2021 Dec 1;18(1):1–10.
View Article
Google Scholar

[51] View Article

[52] Google Scholar

[ref18] 18. Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: A case-control study. BMC Infect Dis. 2019 Apr 3;19(1):305. pmid:30943903
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref19] 19. Egziabhier AG, Zealiyas K, Tilahun R, Girma M, G/Michael G, Deressa T, et al. HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia. J AIDS HIV Treat. 2019 Nov 22;Volume 1(Issue 2):46–57.
View Article
Google Scholar

[58] View Article

[59] Google Scholar

[ref20] 20. Alemayehu T, Abebe W. Second line anti-retroviral therapy failure in a pediatric cohort of an Ethiopian tertiary hospital: a retrospective observational study. Sci Rep. 2020 Dec 1;10(1):8699. pmid:32457309
View Article
PubMed/NCBI
Google Scholar

[61] View Article

[62] PubMed/NCBI

[63] Google Scholar

[ref21] 21. Alene M, Awoke T, Yenit MK, Tsegaye AT. Incidence and predictors of second-line antiretroviral treatment failure among adults living with HIV in Amhara region: A multi-centered retrospective follow-up study. BMC Infect Dis. 2019 Jul 9;19(1):599. pmid:31288748
View Article
PubMed/NCBI
Google Scholar

[65] View Article

[66] PubMed/NCBI

[67] Google Scholar

[ref22] 22. Zenebe Haftu A, Desta AA, Bezabih NM, Bayray Kahsay A, Kidane KM, Zewdie Y, et al. Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study. Edward ST, editor. PLoS One. 2020 Sep 28;15(9):e0239191. pmid:32986756
View Article
PubMed/NCBI
Google Scholar

[69] View Article

[70] PubMed/NCBI

[71] Google Scholar

[ref23] 23. Teeraananchai S, Kerr SJ, Gandhi M, Do VC, Van Nguyen L, Tran DNH, et al. Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):253–6. pmid:31125411
View Article
PubMed/NCBI
Google Scholar

[73] View Article

[74] PubMed/NCBI

[75] Google Scholar

[ref24] 24. Ségéral O, Nerrienet E, Neth S, Spire B, Khol V, Ferradini L, et al. Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Front Public Heal. 2018 Mar 19;6:63. pmid:29662875
View Article
PubMed/NCBI
Google Scholar

[77] View Article

[78] PubMed/NCBI

[79] Google Scholar

[ref25] 25. Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: Adolescents at high risk of failure. J Int AIDS Soc. 2017;20(1): pmid:28953325
View Article
PubMed/NCBI
Google Scholar

[81] View Article

[82] PubMed/NCBI

[83] Google Scholar

[ref26] 26. Seid A, Cherie N, Ahmed K. Determinants of Virologic Failure Among Adults on Second Line Antiretroviral Therapy in Wollo, Amhara Regional State, Northeast Ethiopia. HIV/AIDS—Res Palliat Care. 2020 Nov 10;Volume 12:697–706. pmid:33204171
View Article
PubMed/NCBI
Google Scholar

[85] View Article

[86] PubMed/NCBI

[87] Google Scholar

[ref27] 27. Onoya D, Nattey C, Budgell E, Van Den Berg L, Maskew M, Evans D, et al. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa. AIDS Patient Care STDS. 2017 May 1;31(5):205–12. pmid:28445088
View Article
PubMed/NCBI
Google Scholar

[89] View Article

[90] PubMed/NCBI

[91] Google Scholar

[ref28] 28. Adigeh DT, Abebe BG. The Practice of Peri-Urban Land Acquisition by Expropriation for Housing Purposes and the Implications: The Case of Bahir Dar, Ethiopia. Urban Sci. 2023 Jun 1;7(2):
View Article
Google Scholar

[93] View Article

[94] Google Scholar

[ref29] 29. Mekonen D, Arega Bazezew |, Mesfin Anteneh |, Kassie T. Analysis of food security using various indicators for policy implications: Empirical evidence from the two large cities of Bahir Dar and Gondar, the Amhara region, Ethiopia. Geo Geogr Environ. 2023 Jan 1;10(1):e00122.
View Article
Google Scholar

[96] View Article

[97] Google Scholar

[ref30] 30. Asemahagn MA. The functionality status and challenges of electronic health management information system: The case of public health centres in Amhara Region, Ethiopia. Cogent Med. 2018 Jan 1;5(1):1437672.
View Article
Google Scholar

[99] View Article

[100] Google Scholar

[ref31] 31. Tegegne AD, Negewo MAP, Desta MK, Nedessa KG, Belaye HM. CITY PROFILE GONDAR. In: Social Inclusion and Energy Managment for Informal Urban Settlements. GOdar Ethiopia: Semantic Scholar; 2020. p. 1–28.

[ref32] 32. Taddese AA, Gashaye KT, Dagne H, Andualem Z. Maternal and partner’s level of satisfaction on the delivery room service in University of Gondar Referral Hospital, northwest, Ethiopia: a comparative cross-sectional study. BMC Heal Serv Res 2020 201. 2020 Mar 19;20(1):1–8.
View Article
Google Scholar

[103] View Article

[104] Google Scholar

[ref33] 33. De los Rios P, Okoli C, Punekar Y, Allan B, Muchenje M, Castellanos E, et al. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Prev Med (Baltim). 2020 Oct 1;139(106182): pmid:32593732
View Article
PubMed/NCBI
Google Scholar

[106] View Article

[107] PubMed/NCBI

[108] Google Scholar

[ref34] 34. Tsegaye AT, Wubshet M, Awoke T, Addis Alene K. Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: A multicentre retrospective follow-up study. BMJ Open. 2016 Dec 1;6(12):e012537. pmid:27932339
View Article
PubMed/NCBI
Google Scholar

[110] View Article

[111] PubMed/NCBI

[112] Google Scholar

[ref35] 35. Usman SO, Ajayi OM, Ebiekura O, Egbonrelu N, Ebhojie G, Ariyo AO. Evidence of virological failure in patients on second-line anti-retroviral therapy in Southwestern Nigeria: An indication for HIV drug resistance testing. African J Clin Exp Microbiol. 2021 Jul 2;22(3):415–9.
View Article
Google Scholar

[114] View Article

[115] Google Scholar

[ref36] 36. Silva Junior G, Parente Filho SL, Soares D, Alencar R, Peixoto T, Nogueira I, et al. Factors associated with poor adherence to ant-retroviral therapy among HIV/AIDS patients attending care and treatment clinic at Mnazi Mmoja Hospital, Zanzibar. Int J Infect Dis. 2018 Aug 1;73:250–1.
View Article
Google Scholar

[117] View Article

[118] Google Scholar

[ref37] 37. Kenneth L. Schaecher FACP, CPC MD. The Importance of Treatment Adherence in HIV. Suppl Featur Publ. 2013;19(12 Suppl):1–9.
View Article
Google Scholar

[120] View Article

[121] Google Scholar

[ref38] 38. Yeshaneh A, Lencha A, Aweke AM, Dessalew Y, Wale T, Mekuriya E, et al. Consistent condom utilization and associated factors among HIV positive clients attending ART clinic at Pawi general hospital, North West Ethiopia. PLoS One. 2021 Dec 1;16(12):e0261581. pmid:34932611
View Article
PubMed/NCBI
Google Scholar

[123] View Article

[124] PubMed/NCBI

[125] Google Scholar

[ref39] 39. Ali MS, Tesfaye Tegegne E, Kassa Tesemma M, Tesfaye Tegegne K. Consistent Condom Use and Associated Factors among HIV-Positive Clients on Antiretroviral Therapy in North West Ethiopian Health Center, 2016 GC. AIDS Res Treat. 2019;2019: pmid:31007955
View Article
PubMed/NCBI
Google Scholar

[127] View Article

[128] PubMed/NCBI

[129] Google Scholar

[ref40] 40. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA. 2001 Nov 28;286(20):2560–7. pmid:11722270
View Article
PubMed/NCBI
Google Scholar

[131] View Article

[132] PubMed/NCBI

[133] Google Scholar

[ref41] 41. Mugisha K, Ocero A, Semafumu E, Ciccio L, Muwanika RF, Otim J, et al. Retention of HIV positive persons in antiretroviral therapy programs in post-conflict northern uganda-baseline survey of 17 health units. Rep by North Uganda Malaria, AIDS, Tuberc Program. 2009;7(2):8–42.
View Article
Google Scholar

[135] View Article

[136] Google Scholar

[ref42] 42. Dessalegn NG, Hailemichael RG, Shewa-amare A, Sawleshwarkar S, Lodebo B, Amberbir A, et al. HIV Disclosure: HIV-positive status disclosure to sexual partners among individuals receiving HIV care in Addis Ababa, Ethiopia. PLoS One. 2019 Feb 1;14(2):e0211967. pmid:30768642
View Article
PubMed/NCBI
Google Scholar

[138] View Article

[139] PubMed/NCBI

[140] Google Scholar

[ref43] 43. Izudi J, Okoboi S, Lwevola P, Kadengye D, Bajunirwe F. Effect of disclosure of HIV status on patient representation and adherence to clinic visits in eastern Uganda: A propensity-score matched analysis. PLoS One. 2021 Oct 19;16(10):e0258745. pmid:34665842
View Article
PubMed/NCBI
Google Scholar

[142] View Article

[143] PubMed/NCBI

[144] Google Scholar

[ref44] 44. Dessie G, Wagnew F, Mulugeta H, Amare D, Jara D, Leshargie CT, et al. The effect of disclosure on adherence to antiretroviral therapy among adults living with HIV in Ethiopia: A systematic review and meta-analysis. BMC Infect Dis. 2019 Jun 17;19(1):1–8.
View Article
Google Scholar

[146] View Article

[147] Google Scholar

[ref45] 45. Beima-Sofie KM, Brandt L, Hamunime N, Shepard M, Uusiku J, John-Stewart GC, et al. Pediatric HIV Disclosure Intervention Improves Knowledge and Clinical Outcomes in HIV-Infected Children in Namibia. J Acquir Immune Defic Syndr. 2017 May 1;75(1):18–26. pmid:28114186
View Article
PubMed/NCBI
Google Scholar

[149] View Article

[150] PubMed/NCBI

[151] Google Scholar

[ref46] 46. Melis Berhe T, Lemma L, Alemayehu A, Ajema D, Glagn M, Dessu S. HIV-Positive Status Disclosure and Associated Factors among HIV-Positive Adult Patients Attending Art Clinics at Public Health Facilities of Butajira Town, Southern Ethiopia. AIDS Res Treat. 2020;7(16): pmid:33204528
View Article
PubMed/NCBI
Google Scholar

[153] View Article

[154] PubMed/NCBI

[155] Google Scholar

Figures

Abstract

Background

Objective

Method and materials

Results

Conclusion and recommendations

Introduction

Methods and materials

Study settings

Study design and period

Source population

Study population

Inclusion and exclusion criteria

Sample size determination and sampling techniques

Study variables

Data collection tools and techniques

Data quality managements

Data processing and analysis

Ethical statement

Definition of terms

Results

Socio-demographic and behavioral characteristics

Clinical and immunological characteristics

Factors associated to second line ART virological failure

Discussion

Conclusions

Recommendations

Supporting information

S1 File. Annex I. Information sheet.

S2 File. Annex II Consent form.

S1 Table. Socio demographic characteristics of the patients.

S2 Table. Behavioral characteristics of the patients.

S3 Table. Clinical and immunological features of the patients.

S4 Table. Factors for second line ART Virological failure.

Acknowledgments

References